# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Joel Beatty maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to $3.
HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, ...
- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glyc...
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the Company will host a ...
HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.